Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1501 + Adebrelimab in advanced malignant tumors
NCT07073534Phase 2Recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Jul 2025
- Primary completion
- Dec 2027
- Modality
- Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-1501 in malignant neoplasm, sponsored by Hengrui Therapeutics. Started Jul 2025; status: recruiting.
02
Drugs
SHR-1501
03
Conditions
malignant neoplasm
Beyond the preview
Go deeper on NCT07073534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07073534.